Turkiye Klinikleri Cardiovascular Sciences

.: ORIGINAL RESEARCH
Restenoz Hastalarında Serum ApoM ve Serum Lipid Seviyeleri Arasındaki İlişkinin Araştırılması
The Relationship Between Serum ApoM and Lipid Levels in Restenosis Patients
Gülçin ÖZKARAa, Zahra JAVADOVAa, Ezgi Irmak ASLANa, Onur KILIÇARSLANb, Özgür Selim SERb, Oğuz ÖZTÜRKa, Ahmet YILDIZb, Hülya YILMAZ AYDOĞANa
aİstanbul Üniversitesi Aziz Sancar Deneysel Tıp Araştırma Enstitüsü, Moleküler Tıp ABD, İstanbul, TÜRKİYE
bİstanbul Üniversitesi-Cerrahpaşa Kardiyoloji Enstitüsü, Kardiyoloji Bölümü, İstanbul, TÜRKİYE
Turkiye Klinikleri J Cardiovasc Sci. 2020;32(2):75-83
doi: 10.5336/cardiosci.2020-75998
Article Language: TR
Full Text
ÖZET
 Amaç: Apolipoprotein M (ApoM) çoğunlukla (~%5) yüksek yoğunluklu lipoprotein (HDL) ve az miktarda (<%2) düşük yoğunluklu lipoprotein (LDL) içeriğinde bulunan yeni bir antiaterosklerotik proteindir. Ters kolesterol transportu aracılığıyla HDL metabolizmasında önemli rol oynadığı bilinen ApoM'nin, son çalışmalarda LDL oksidasyonu ve ateroskleroza karşı koruyucu etkileri olduğu belirtilmiştir. Buna karşın ApoM ve hastalıkların ilişkisini araştıran klinik çalışmalar sınırlı sayıdadır. Bu sebeple ApoM'nin kolesterol metabolizmasındaki etkilerine dayanarak çalışmamızda, restenoz hastalarında ve sağlıklı kontrollerde serum ApoM ve lipid seviyeleri arasındaki ilişkiyi araştırmayı amaçladık. Bu çalışma, restenoz hastalarında serum ApoM ve lipid seviyeleri arasındaki ilişkiyi gösteren literatürdeki ilk çalışmadır. Gereç ve Yöntemler: Çalışmamıza, 36 restenoz hastası ve 42 sağlıklı kontrol dâhil edilmiştir. Serum ApoM seviyeleri, ELISA yöntemiyle ölçülmüştür. Bulgular: Hasta grubunda serum ApoM (p=0,022), totalkolesterol (Total-K) (p=0,008) ve HDL-kolesterol (HDL-K) (p<0,001) seviyeleri sağlıklı kontrollerden daha düşük bulunurken, açlık kan glukozu ve HbA1c (p<0,001) ve trigliserid (TG) seviyeleri (p=0,002) yüksek bulunmuştur. Ayrıca restenoz hastalarında yüksek TG (≥150 mg/dL) ve LDL-kolesterol (LDL-K) (≥130 mg/dL) risk eşik değerlerinin, yüksek ApoM seviyeleri ile ilişkili olduğu tespit edilmiştir (sırasıyla, p=0,038; p=0,041). Bu ilişki kontrol grubunda gözlenmemiştir (p>0,05). Sonuç: Restenoz hastalarında, serum ApoM seviyeleri yalnızca HDL-K ile değil aynı zamanda Total-K, TG ve LDL-K seviyeleri ile de anlamlı pozitif korelasyon göstermiştir. Bu sonuçlar ApoM seviyelerinin, TG ve kolesterol seviyelerine etki ederek restenoz gelişimine katkı sağlayabileceğini göstermektedir.

Anahtar Kelimeler: Apolipoprotein M; HDL; LDL; kolesterol; trigliserid; restenoz
ABSTRACT
 Objective: Apolipoprotein M (ApoM) is a novel antiatherosclerotic protein which is present predominantly (~5%) in high density lipoprotein (HDL) and in trace amounts (<2%) in low density lipoprotein (LDL). In recent studies, it is reported that ApoM which is known to play important role in HDL metabolism via revers cholesterol transport, has protective effects against LDL oxidation and atherosclerosis. However, clinical studies revealing the association between ApoM and diseases are very limited. Therefore, we aimed to investigate the relationship between serum ApoM and lipid levels in restenosis patients and healthy controls on the basis of its effects on cholesterol metabolism. This is the first study revealing the association between serum ApoM and lipid levels in restenosis patients. Material and Methods: Thirty-six restenosis patients and 42 healthy controls were included in our study. Serum ApoM levels were measured by ELISA method. Results: The serum ApoM (p=0.022), total-cholesterol (Total-C) (p=0.008) and HDLcholesterol (HDL-C) (p<0.001) levels of patients were lower than the control group, while fasting blood glucose, HbA1c (p<0.001) and triglyceride (TG) (p=0.002) levels were higher. In addition, higher risk threshold values for serum TG (≥150 mg/dL) and LDL-cholesterol (LDL-C) (≥130 mg/dL) in the restenosis group were detected to be associated with higher ApoM levels in the restenosis patient group (p=0.038 and p=0.041, respectively). However, this relationship was not observed in control group (p>0.05). Conclusion: Serum ApoM level exhibited a significant, positive correlation not only with the HDL-C level, but also with the Total-C, TG and LDL-C levels in patients with restenosis. These results indicated that the serum ApoM levels may affects the serum TG and cholesterol levels so that contributes to the development of restenosis.

Keywords: Apolipoprotein M; HDL; LDL; cholesterol; triglyceride; restenosis
REFERENCES:
  1. Mendis S, Puska P, Norrving B; World Health Organization. Global Atlas on Cardiovascular Disease Prevention and Control. Geneva: World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization; 2011. p.166.
  2. Onat A, Aydin M, Köroğlu B, Ornek E, Altay S, Celik E, et al. [TARF Survey 2011: mortality and performance in the long-term follow-up]. Turk Kardiyol Dern Ars. 2012;40(2):117-21. [Crossref]  [PubMed] 
  3. Thanassoulis G, Vasan RS. Genetic cardiovascular risk prediction: will we get there? Circulation. 2010;122(22):2323-34. [Crossref]  [PubMed]  [PMC] 
  4. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995;15(5):551-62. [Crossref]  [PubMed] 
  5. Mendis S, Nordet P, Fernandez-Britto JE, Sternby N; For the Pathobiological Determinants of Atherosclerosis in Youth (PBDAY) Research Group. Atherosclerosis in children and young adults: An overview of the World Health Organization and International Society and Federation of Cardiology Study on Pathobiological Determinants of Atherosclerosis in Youth Study (1985-1995). Prevention and Control. 2005;1(1):3-15. [Crossref] 
  6. Davis NE. Atherosclerosis--an inflammatory process. J Insur Med. 2005;37(1):72-5.
  7. Borissoff JI, Heeneman S, Kilinç E, Kassák P, Van Oerle R, Winckers K, et al. Early atherosclerosis exhibits an enhanced procoagulant state. Circulation. 2010;122(8):821-30. [Crossref]  [PubMed] 
  8. Nordmann AJ, Hengstler P, Leimenstoll BM, Harr T, Young J, Bucher HC. Clinical outcomes of stents versus balloon angioplasty in non-acute coronary artery disease: a meta-analysis of randomized controlled trials. Eur Heart J. 2004;25(1):69-80. [Crossref]  [PubMed] 
  9. Indolfi C, Pavia M, Angelillo IF. Drug-eluting stents versus bare metal stents in percutaneous coronary interventions (a meta-analysis). Am J Cardiol. 2005;95(10):1146-52. [Crossref]  [PubMed] 
  10. Inoue T, Node K. Molecular basis of restenosis and novel issues of drug-eluting stents. Circ J. 2009;73(4):615-21. [Crossref]  [PubMed] 
  11. Xu N, Dahlbäck B. A novel human apolipoprotein (apoM). J Biol Chem. 1999;274(44):31286-90. [Crossref]  [PubMed] 
  12. Huang LZ, Gao JL, Pu C, Zhang PH, Wang LZ, Feng G, et al. Apolipoprotein M: research progress, regulation and metabolic functions (Review). Mol Med Rep. 2015;12(2):1617-24. [Crossref]  [PubMed] 
  13. Christoffersen C, Nielsen LB, Axler O, Andersson A, Johnsen AH, Dahlbäck B. Isolation and characterization of human apolipoprotein M-containing lipoproteins. J Lipid Res. 2006;47(8):1833-43. [Crossref]  [PubMed] 
  14. Sramkova V, Berend S, Siklova M, Caspar-Bauguil S, Carayol J, Bonnel S, et al. Apolipoprotein M: a novel adipokine decreasing with obesity and upregulated by calorie restriction. Am J Clin Nutr. 2019;109(6):1499-510. [Crossref]  [PubMed] 
  15. Tavernier G, Caspar-Bauguil S, Viguerie N. Apolipoprotein M: new connections with diet, adipose tissue and metabolic syndrome. Curr Opin Lipidol. 2020;31(1):8-14. [Crossref]  [PubMed] 
  16. Wang X, Wang F. Vascular protection by high-density lipoprotein-associated sphingosine-1- phosphate. J Geriatr Cardiol. 2017;14(11):696-702.
  17. Christoffersen C, Jauhiainen M, Moser M, Porse B, Ehnholm C, Boesl M, et al. Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock out mice. J Biol Chem. 2008;283(4):1839 47. [Crossref]  [PubMed] 
  18. Santamarina Fojo S, Lambert G, Hoeg JM, Brewer Jr HB. Lecithin cholesterol acyltransferase: role in lipoprotein metabolism, reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol. 2000;11(3):267 75. [Crossref]  [PubMed] 
  19. Wolfrum C, Poy MN, Stoffel M. Apolipoprotein M is required for prebeta HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med. 2005;11(4):418 22. [Crossref]  [PubMed] 
  20. Xu WW, Zhang Y, Tang YB, Xu YL, Zhu HZ, Ferro A, et al . A genetic variant of apolipo-protein M increases susceptibility to coronary artery disease in a Chinese population. Clin Exp Pharmacol Physiol. 2008;35(5-6):546 51. [Crossref]  [PubMed] 
  21. Jiao GQ, Yuan ZX, Xue YS, Yang CJ, Lu CB, Lu ZQ, et al. A prospective evaluation of apolipoprotein M gene T 778C polymorphism in relation to coronary artery disease in Han Chinese. Clin Biochem. 2007;40(15):1108 12. [Crossref]  [PubMed] 
  22. Zhang Z, Chu G, Yin RX. Apolipoprotein M T 778C polymorphism is associated with serum lipid levels and the risk of coronary artery disease in the Chinese population: a meta analysis. Lipids Health Dis. 2013;12:135. [Crossref]  [PubMed]  [PMC] 
  23. Zhou JW, Tsui SKW, Ng MCY, Geng H, Li SK, So WY, et al. Apolipoprotein M gene (APOM) polymorphism modifies metabolic and disease traits in type 2 diabetes. PLoS One. 2011;6(2):e17324. [Crossref]  [PubMed]  [PMC] 
  24. Huang Y, Liu Y, Jiang L, Sun R, Zhang H, Liu R, Xu N. Apolipoprotein m (APOM) levels and APOM rs805297 G/T polymorphism are associated with increased risk for rheumatoid arthritis. Joint Bone Spine. 2014;81(1):32-6. [Crossref]  [PubMed] 
  25. Burkart KM, Manichaikul A, Wilk JB, Ahmed FS, Burke GL, Enright P, et al. APOM and high density lipoprotein cholesterol are associated with lung function and per cent emphysema. Eur Respir J. 2014;43(4):1003 17. [Crossref]  [PubMed]  [PMC] 
  26. Christoffersen C, Nielsen LB. Apolipoprotein M: bridging HDL and endothelial function. Curr Opin Lipidol. 2013;24(4):295-300. [Crossref]  [PubMed] 
  27. Blaho VA, Hla T. Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors. Chem Rev. 2011;111(10):6299-320. [Crossref]  [PubMed]  [PMC] 
  28. Frej C, Linder A, Happonen KE, Taylor FB, Lupu F, Dahlbäck B. Sphingosine 1-phosphate and its carrier apolipoprotein M in human sepsis and in Escherichia coli sepsis in baboons. J Cell Mol Med. 2016;20(6):1170-81. [Crossref]  [PubMed]  [PMC] 
  29. Tao R, Hoover HE, Honbo N, Kalinowski M, Alano CC, Karliner JS, et al. High-density lipoprotein determines adult mouse cardiomyocyte fate after hypoxia-reoxygenation through lipoprotein-associated sphingosine 1-phosphate. Am J Physiol Heart Circ Physiol. 2010;298(3):H1022-8. [Crossref]  [PubMed]  [PMC] 
  30. Sattler K, Gräler M, Keul P, Weske S, Reimann CM, Jindrová H, et al. Defects of high-density lipoproteins in coronary artery disease caused by low sphingosine-1-phosphate content: correction by sphingosine-1-phosphate-loading. J Am Coll Cardiol. 2015;66(13):1470-85. [Crossref]  [PubMed] 
  31. Kurano M, Tsuneyama K, Morimoto Y, Shimizu T, Jona M, Kassai H, et al. Apolipoprotein M protects lipopolysaccharide-treated mice from death and organ injury. Thromb Haemost. 2018;118(6):1021-35. [Crossref]  [PubMed] 
  32. Kappelle PJWH, Ahnström J, Dikkeschei BD, de Vries R, Sluiter WJ, Wolffenbuttel BHR, et al. Plasma apolipoprotein M responses to statin and fibrate administration in type 2 diabetes mellitus. Atherosclerosis. 2010;213(1):247-50. [Crossref]  [PubMed] 
  33. Thongtang N, Diffenderfer MR, Ooi EMM, Barrett PHR, Turner SM, Le NA, et al. Metabolism and proteomics of large and small dense LDL in combined hyperlipidemia: effects of rosuvastatin. J Lipid Res. 2017;58(7):1315-24. [Crossref]  [PubMed]  [PMC] 
  34. Ahnström J, Axler O, Jauhiainen M, Salomaa V, Havulinna AS, Ehnholm C, et al. Levels of apolipoprotein M are not associated with the risk of coronary heart disease in two independent case-control studies. J Lipid Res. 2008;49(9):1912-7. [Crossref]  [PubMed] 
  35. Chirinos JA, Zhao L, Jia Y, Frej C, Adamo L, Mann D, et al. Reduced apolipoprotein M and adverse outcomes across the spectrum of human heart failure. Circulation. 2020;141(18):1463-76. [Crossref]  [PubMed] 
  36. Memon AA, Bennet L, Zöller B, Wang X, Palmér K, Dahlbäck B, et al. The association between apolipoprotein M and insulin resistance varies with country of birth. Nutr Metab Cardiovasc Dis. 2014;24(11):1174-80. [Crossref]  [PubMed] 
  37. Kurano M, Tsukamoto K, Shimizu T, Kassai H, Nakao K, Aiba A, et al. Protection against insulin resistance by apolipoprotein M/sphingosine-1-phosphate. Diabetes. 2020;69(5):867-81. [Crossref]  [PubMed] 
  38. Frej C, Mendez AJ, Ruiz M, Castillo M, Hughes TA, Dahlbäck B, et al. A shift in ApoM/S1P between HDL-particles in women with type 1 diabetes mellitus is associated with impaired anti-inflammatory effects of the ApoM/S1P complex. Arterioscler Thromb Vasc Biol. 2017;37(6):1194-205. [Crossref]  [PubMed] 
  39. He L, Wu P, Tan L, Le B, Du W, Shen T, et al. Characteristics of lipid metabolism including serum apolipoprotein M levels in patients with primary nephrotic syndrome. Lipids Health Dis. 2017;16(1):167. [Crossref]  [PubMed]  [PMC] 
  40. Sørensen IM, Bertelsen M, Freese E, Lindhard K, Ullum H, Feldt-Rasmussen B, et al. Apolipoprotein M in patients with chronic kidney disease. Atherosclerosis. 2018;275:304-11. [Crossref]  [PubMed] 
  41. Christoffersen C, Benn M, Christensen PM, Gordts PLSM, Roebroek AJM, Frikke-Schmidt R, et al. The plasma concentration of HDL-associated apoM is influenced by LDL receptor-mediated clearance of apoB-containing particles. J Lipid Res. 2012;53(10):2198-204. [Crossref]  [PubMed]  [PMC] 
  42. Axler O, Ahnström J, Dahlbäck B. An ELISA for apolipoprotein M reveals a strong correlation to total cholesterol in human plasma. J Lipid Res. 2007;48(8):1772-80. [Crossref]  [PubMed] 

.: Up To Date

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com